The HORIZON 2020 program offers good funding opportunities for
SMEs. Wiborg assisted in getting more than € 7.6 million from EU
and other public sources.
Prophylix Pharma AS coordinates the PROFNAIT consortium
which was granted €6 million under EU's FP7 programme to develop a
prophylactic treatment of FNAIT.
Executives from the Scandinavian and German biotech industries
participated in the business development course on Valuation,
Deal Structuring and Negotiation in life science.
At BIO, Wiborg assisted clients in commercializing selected drug
development projects and in identifying and assessing a number
of in-licensing opportunities.
Copyright © 2017 Wiborg ApS. All rights reserved.